Spero Therapeutics, Inc. (SPRO) KPIs and segments
Close on Nov 12, 2026Market cap $58.23MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Spero Therapeutics's business
Spero Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Collaboration revenue($M) | 0 | 0 | 12.6 | 0 | 0 | 0.01 | 0.05 | 0.07 | 0.11 | 0.14 | |
Collaboration revenue - related party($M) | 0 | 0.26 | 27.1 | 3.05 | 11.8 | 5.10 | 9.30 | 7.75 | 5.90 | 4.06 | |
Grant Revenue($M) | 0 | 0 | 1.64 | 2.39 | 2.39 | 0.76 | 5.69 | 5.65 | 4.18 | 5.06 | |
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-12.
See a number that looks wrong?